Journal article
Biologics in Asthma: A Molecular Perspective to Precision Medicine
Abstract
Recent developments in therapeutic strategies have provided alternatives to corticosteroids as the cornerstone treatment for managing airway inflammation in asthma. The past two decades have witnessed a tremendous boost in the development of anti-cytokine monoclonal antibody (mAb) therapies for the management of severe asthma. Novel biologics that target eosinophilic inflammation (or type 2, T2 inflammation) have been the most successful at …
Authors
Salter B; Lacy P; Mukherjee M
Journal
Frontiers in Pharmacology, Vol. 12, ,
Publisher
Frontiers
DOI
10.3389/fphar.2021.793409
ISSN
1663-9812